2 cheap ftse ftse growth actions for Isa investors to consider!

With Isa's deadline approaching quickly, I have been touring the London stock market for last minute additions. Today I have been digging in the Ftse 250 For the best growth actions in the United Kingdom that are considered to consider buying.

My research has unearthed the following garbage earlier heroes:

As you can see, both FTSE 250 shares are proposed to offer a two -digit earning growth in the current financial year.

They are also negotiated with a multiple profit price growth (PEP) below the value score of one.

Here is why I think it is worth a serious consideration of the cunning Isa investors.

Chemistry

Chemistry, which manufactures countermeasures and sensors for the defense industry, is thriving as the expenditure of arms accelerates in the West.

His last victory of the contract last month was £ 26m, an agreement of several years with “A main US contractor.“To supply radar technology.

The news continues that income increased by 8% in the last financial year of Chemring (until October 2024). His order book also jumped to register maximums of £ 1.04 billion in the last fiscal period.

With the increase in geopolitical tensions and NATO budgets increase, the FTSE 250 company looks in a good way to earn many more businesses in the future. This should be supported by capacity increases for its countermeasures in the United States and the United Kingdom, and the possible expansion in Norway (which is currently exploring).

I am also excited by the improvement of Chemring's presence in rapid growth areas of artificial intelligence (ai), Cybernetic war and electronic security. These phenomena promoted sales in their Roke unit 13% higher in Financial 2024.

The problems of the supply chain in the defense industry remain a threat. And on the side of sales, the demand of the United States could be negatively affected by the expenses reviews of the Efficient Department of the Government of Elon Musk (Doge).

However, in general, I think Chemring is one of the main shares for growth investors. And particularly at today's price.

Needle Medical Care

With its great footprint of 39 hospitals and 50 clinics (and other facilities), Spire is one of the largest private medical services providers in the United Kingdom. As a result, sales and profits rise as the severe pressure on the National Health Service (NHS) is dragged.

The reasons for this commercial boom are double. The NHS -related business is growing as the government pays private medical care providers to eliminate patients. The income of this source increased 5.2% in the six months until June.

Trade is also booming as people avoid waiting lists of long NHS and finance their own treatments. Private income from Spire (through the medical insurance of self-paid and private) grew by 5.1% between January and June 2024.

At the moment, there are 7.5 million people waiting for the treatment of NHS. This will take a long time to clear, giving Spire an excellent gain visibility.

As the Population of Elders of Great Britain grows, medical care companies such as this also have a significant long -term profit potential. The National Statistics Office believes that one in four British will have 65 years or more for 2050.

I think Spire is a superior action to consider, despite the fact that the shortage of medical personnel (and their impact on costs) are still a threat.